HSCS (HeartSciences) Quality Rank


HSCS HeartSciences Inc HSCS
42 GF Score
Price $2.81
GF Value $2.60
Valuation Fairly Valued
! 7 Warning Signs
View Full Analysis

What is HeartSciences Quality Rank?

The Quality Rank measures the business quality of a company relative to other companies. It is ranked based on the strength of the balance sheet, as well as the profitability and growth of the business. The ranked companies are split in equal numbers and then ranked from 1 to 10, with 10 being the highest.

The rank of balance sheet (30%)

The rank of balance sheet is done through the ranking of:
  • Interest coverage
  • Zscore
  • Debt to revenue
  • Equity to asset
  • Cash to debt

The rank of Profitability (70%)

The ranking of Profitability is done by ranking:
  • Operating margin mean rank (10-year mean average profit margine)
  • Operating margin growth rank
  • Fscore
  • Predictability rank
  • Revenue growth rank (5 year), when the growth is higher than 25%, set it as 25%
  • Num of year profit (number of years that is profitable within the last 10 years)
  • ROIC median (10-year median of ROIC)

HeartSciences Quality Rank Related Terms

HSCS
42GF Score
HeartSciences Inc HSCS
Quality Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is HeartSciences (HSCS) Overvalued in 2026?

Based on GuruFocus' analysis, HeartSciences stock appears to be overvalued. The current stock price of $2.81 is trading 8.1% above its estimated GF Value™ of $2.60. GuruFocus considers HeartSciences to be Fairly Valued.

Key valuation signals for HSCS:

  • Quality Rank:
  • GF Value™: $2.60 vs. price of $2.81 (8.1% above fair value)
  • GF Score™: 42/100 with 7 warning signs

No single metric tells the full story. See the HSCS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

HeartSciences Business Description

Address 550 Reserve Street, Suite 360, Southlake, TX, USA, 76092
HeartSciences Inc is an artificial intelligence (AI)-powered medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease. Its objective is to improve healthcare by making it a far more valuable cardiac screening tool, particularly in frontline or point-of-care clinical settings. It is developing a suite of AI-ECG diagnostic solutions for use in any healthcare care setting, either via MyoVista Insights cloud-platform using one of the millions of ECG devices currently in clinical use or via MyoVista wavECG Device.
42GF Score

Get the complete analysis for HSCS

Quality Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.81
Price
$2.60
GF Value